OP Asset Management Ltd Invests $35.77 Million in Gilead Sciences, Inc. $GILD

OP Asset Management Ltd bought a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) in the first quarter, Holdings Channel.com reports. The firm bought 256,653 shares of the biopharmaceutical company’s stock, valued at approximately $35,770,000.

Several other large investors have also recently modified their holdings of the business. Aviva PLC increased its stake in Gilead Sciences by 5.4% in the 4th quarter. Aviva PLC now owns 1,156,738 shares of the biopharmaceutical company’s stock worth $141,978,000 after acquiring an additional 59,782 shares during the last quarter. Nordea Investment Management AB boosted its position in shares of Gilead Sciences by 16.5% during the 4th quarter. Nordea Investment Management AB now owns 5,138,699 shares of the biopharmaceutical company’s stock valued at $630,056,000 after acquiring an additional 726,101 shares during the last quarter. Life Cycle Investment Partners Ltd purchased a new position in shares of Gilead Sciences during the fourth quarter worth about $1,418,000. Beacon Investment Advisory Services Inc. grew its holdings in shares of Gilead Sciences by 10.3% during the fourth quarter. Beacon Investment Advisory Services Inc. now owns 111,531 shares of the biopharmaceutical company’s stock worth $13,689,000 after purchasing an additional 10,449 shares in the last quarter. Finally, SageView Advisory Group LLC increased its position in shares of Gilead Sciences by 159.5% in the third quarter. SageView Advisory Group LLC now owns 23,940 shares of the biopharmaceutical company’s stock worth $2,657,000 after purchasing an additional 14,715 shares during the last quarter. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Insider Activity at Gilead Sciences

In other Gilead Sciences news, insider Johanna Mercier sold 28,000 shares of Gilead Sciences stock in a transaction on Friday, May 15th. The stock was sold at an average price of $131.29, for a total transaction of $3,676,120.00. Following the completion of the transaction, the insider owned 125,779 shares in the company, valued at approximately $16,513,524.91. The trade was a 18.21% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Patrick O’day sold 15,000 shares of Gilead Sciences stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $131.46, for a total value of $1,971,900.00. Following the completion of the transaction, the chief executive officer directly owned 617,567 shares of the company’s stock, valued at approximately $81,185,357.82. This represents a 2.37% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 68,000 shares of company stock valued at $8,930,150 in the last 90 days. Corporate insiders own 0.30% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on the stock. Leerink Partners dropped their target price on shares of Gilead Sciences from $148.00 to $146.00 in a research report on Friday, May 8th. Morgan Stanley lowered their price objective on shares of Gilead Sciences from $175.00 to $168.00 in a research report on Friday, May 8th. Citigroup lifted their price objective on shares of Gilead Sciences from $156.00 to $165.00 and gave the stock a “buy” rating in a report on Monday, April 13th. Maxim Group raised Gilead Sciences from a “hold” rating to a “buy” rating and set a $165.00 target price for the company in a research note on Wednesday, May 20th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $155.00 price objective on shares of Gilead Sciences in a research note on Tuesday, June 16th. Twenty-five investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $158.41.

Gilead Sciences Stock Performance

Shares of Gilead Sciences stock opened at $125.19 on Thursday. Gilead Sciences, Inc. has a 12 month low of $104.46 and a 12 month high of $157.29. The firm has a market capitalization of $155.43 billion, a P/E ratio of 17.06 and a beta of 0.31. The company has a current ratio of 1.97, a quick ratio of 1.77 and a debt-to-equity ratio of 0.89. The business has a fifty day simple moving average of $130.76 and a two-hundred day simple moving average of $134.31.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.91 by $0.12. Gilead Sciences had a net margin of 30.99% and a return on equity of 48.19%. The company had revenue of $6.96 billion during the quarter, compared to analyst estimates of $6.91 billion. During the same period last year, the business earned $1.81 EPS. Gilead Sciences’s quarterly revenue was up 4.4% compared to the same quarter last year. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. On average, equities analysts forecast that Gilead Sciences, Inc. will post -0.8 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, June 29th. Stockholders of record on Monday, June 15th will be given a $0.82 dividend. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.6%. The ex-dividend date of this dividend is Monday, June 15th. Gilead Sciences’s payout ratio is currently 44.69%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.